Q1 FY27 results reported
As filed · Outcome of Board Meeting
EarningsMajormateriality 77 out of 100
What happened
FactOutcome of Board Meeting. Board of Directors approved the Unaudited Standalone and Consolidated Financial Results of the Company for. The financial results are also available on the website of the Company at www.lauruslabs.com and also on the.
Why it matters
CapitSignal interpretationReported results are the point at which prior management commitments become checkable against audited or reviewed numbers.
What management said before
Prior statements by this company that CapitSignal has recorded changing.
Demand
DelayedEarlierQ4 FY25
We see significant jump in our animal health revenues in FY26.
NowQ4 FY25
Non-ARV formulation revenue will go up from Q3 onwards.
Change
FactTimeline delay
Implication
CapitSignal interpretationThe earlier statement indicated a significant jump in animal health revenues in FY26, while the current statement suggests that non-ARV formulation revenue will increase starting from Q3, implying a delay in the expected timeline for revenue growth.confidence 90%
Watch next
Fact- Margin trend against the prior period
- Cash from operations against reported profit
- Whether prior guidance is reaffirmed
- Majority of FY'27 revenues in our CDMO division will be commercial supplies and I think that much I can make a (management committed by FY27)
- We expect a good growth in CDMO segment. (management committed by FY27)
Evidence
- Outcome of Board Meeting(opens the original filing in a new tab)
- Earlier statement · Q4 FY25
- Latest statement · Q4 FY25
- Earlier statement · Q4 FY26
How CapitSignal classified this
- Reasoning:
- RESULTS base 68; +4 corroborating keywords; +5 quantified amount; matched on subject
- Matched on:
- the filing's own subject line
- Confidence in the event type:
- 90%